CONNEXT

CONNEXT is a clinical-stage biotechnology company headquartered in South Korea that focuses on creating regenerative medicine technologies. Their slogan, "Innovation for Regeneration," perfectly encapsulates their mission. The company, founded in 2017, is dedicated to contributing to human health through integration and innovation. Currently, Connext is developing two main products: CNT101 and CNT201. CNT201 is an injectable recombinant collagenase with promising potential as a treatment for fibrotic diseases such as Dupuytren's contracture and Peyronie's disease. The company received clearance for the IND for Phase 1/2 Dupuytren's contracture study from the US FDA in June 2023, enhancing in early 2024. Meanwhile, CNT101 is an TLR5 agonist-based immune modulator with significant potential as a preventative therapeutic for radiation sickness and aGvHD. Connext successfully conducted an FIH Phase 1 study involving healthy volunteers and received clearance for the Phase I IND application for acute GvHD by the Korea Ministry of Food and Drug Safety (MFDS). Their latest achievement includes a KRW5.00B Series A investment on 16 April 2021 from investors such as KB Investments, LSK Investment, and The Wells Investment. Connext's innovative approach in the Biotechnology and Health Care industries, combined with their successful fundraising and compelling product pipeline, positions them as an ambitious and promising venture worthy of further consideration by potential investors.